Serum level of HDL particles are independently associated with long-term prognosis in patients with coronary artery disease: The GENES study
In: ISSN: 2045-2322, 2020
Online
academicJournal
Zugriff:
International audience ; HDL-Cholesterol (HDL-C) is not an accurate surrogate marker to measure the cardioprotective functions of HDL in coronary artery diseases (CAD) patients. Hence, measurement of other HDL-related parameters may have prognostic superiority over HDL-C. In this work, we examined the predictive value of HDL particles profile for long-term mortality in CAD patients and to compare its informative value to that of HDL-C and apoA-I. HDL particles profiles were measured by nuclear magnetic resonance (NMR) spectroscopy in 214 male participants with stable CAD (45-74 years). Median follow up was 12.5 years with a 36.4% mortality rate. Cardiovascular mortality accounted for 64.5%. Mean concentrations of total HDL particles (HDL-P), small-sized HDL (SHDL-P) and apoA-I were lower in deceased than in surviving patients whereas no difference was observed according to HDL-C and large HDL particles. All NMR-HDL measures were correlated between themselves and with other HDL markers (HDL-C, apoA-I and LpA-I). In a multivariate model adjusted for cardiovascular risk factors and bioclinical variables, HDL-P and SHDL-P displayed the strongest inverse association with all-cause and cardiovascular mortality. Weaker associations were recorded for apoA-I. Based on our results, we conclude that HDL particle profile measured by NMR spectroscopy should be considered to better stratify risk in population at high risk or in the setting of pharmacotherapy.
Titel: |
Serum level of HDL particles are independently associated with long-term prognosis in patients with coronary artery disease: The GENES study
|
---|---|
Autor/in / Beteiligte Person: | Duparc, Thibaut ; Ruidavets, Jean-Bernard ; Genoux, Annelise ; Ingueneau, Cécile ; Najib, Souad ; Ferrières, Jean ; Perret, Bertrand ; Martinez, Laurent, O ; Institut des Maladies Métaboliques et Cardiovasculaires (I2MC) ; Université Toulouse III - Paul Sabatier (UT3) ; Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM) ; Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP) ; Laboratoire de Biochimie CHU Toulouse ; Institut Fédératif de Biologie (IFB) ; Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle Biologie CHU Toulouse ; Centre Hospitalier Universitaire de Toulouse (CHU Toulouse) ; Fédération de Cardiologie CHU Toulouse ; Service Cardiologie CHU Toulouse ; Pôle Cardiovasculaire et Métabolique CHU Toulouse ; Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle Cardiovasculaire et Métabolique CHU Toulouse ; Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse) ; This work was supported by the French National Research Agency (ANR, #ANR-16-CE18-0014-01), European Regional Development Fund (ERDF, Fonds Européen de Développement Régional) and “La Région Occitanie” (Project THERANOVASC n° ESR_R&S_DF-000094/2018-003303/18009464). ; ANR-16-CE18-0014,HDL-NEXT-THERAPEUTICS,Nouvelles thérapies du HDL-cholestérol pour les maladies cardiovasculaire.(2016) |
Link: | |
Zeitschrift: | ISSN: 2045-2322, 2020 |
Veröffentlichung: | HAL CCSD ; Nature Publishing Group, 2020 |
Medientyp: | academicJournal |
DOI: | 10.1038/s41598-020-65100-2 |
Schlagwort: |
|
Sonstiges: |
|